2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 627

Clinical and Immunogenicity Outcomes after Switching Treatment from Innovator Infliximab to Biosimilar Infliximab in Rheumatic Diseases in Daily Clinical Practice
Abstract Number: 628

Analysis of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept Compared to Those Treated with Tumor Necrosis Factor Inhibitors in Clinical Practice
Abstract Number: 629

Golimumab Improves Patient-Reported Outcomes and Socio- and Health-Economic Parameters in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS): Results from a Non-Interventional Clinical Evaluation in Germany
Abstract Number: 630

Strategies for Biological Drug Quantification in Biological Drug Immune Responses
Abstract Number: 631

Biologic Free Remission Rate with Etanercept in Rheumatoid Arthritis: A Potential Role of Gender
Abstract Number: 632

Comparative Improvement in Health-Related Quality of Life for RA Patients Between TNF-α Inhibitors, Other Biologics, and Tofacitinib: Results from a US-Wide Observational Study
Abstract Number: 633

High Similarity Between Ex-Vivo Inhibited Cytokine Profiling By Golimumab and Adalimumab As a Putative Explanation for Inferior Treatment Response to Golimumab after Adalimumab Failure in Rheumatoid Arthritis
Abstract Number: 634

Use of Biosimilars in Clinical Practice: A Swedish National Register-Based Assessment
Abstract Number: 635

Factors Associated to Lack of Adherence to Subcutaneous Biological Medications in Patients with Rheumatoid Arthritis from Spain. Arco Study
Abstract Number: 636

Prospective, Intervention, Multicenter Study of Utility of Biologic Drug Monitoring with Respect to the Efficacy and Cost of Adalimumab Tapering in Patients with Rheumatic Diseases (34-week descriptive data)
Abstract Number: 637

Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs
Abstract Number: 638

A Randomized, Open-Label, Single-Dose, Parallel-Group Trial to Determine the Pharmacokinetics, Safety and Immunogenicity of GP2017, a Proposed Adalimumab Biosimilar, Following a Single Subcutaneous Injection By an Autoinjector or Prefilled Syringe in Healthy Male Subjects
Abstract Number: 639

Switching to Biosimilars in Rheumatology: Evidence-Based Practice
Abstract Number: 640

Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate
Abstract Number: 641

Reduction of Concomitant Oral Methotrexate or Corticosteroids in Combination Treatment with Adalimumab Does Not Affect Effectiveness in Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].